Clinical trials: Chronic Hepatitis, B Virus
Hepatitis B, ESRD (End Stage Renal Disease)
Comparing Hepatitis B Vaccination Schedules in Patients on Hemodialysis
People with kidney failure who are on dialysis have a weaker immune response to the hepatitis B vaccine than healthy people. Even after vaccination, many dialysis patients do not develop enough protection against hepatitis B…
- Conditions
- Hepatitis B, ESRD (End Stage Renal Disease), Kidney Failure, Chronic
- Trial name
- 3v4-HEP-DOSE (NCT07784452)
- Testing
- Recombinant Hepatitis B Vaccine - 3-Dose Schedule, Recombinant Hepatitis B Vaccine - 4-Dose Schedule
- Where
- Pakistan
- Volunteers
- 104 people
- Sponsor
- Jinnah Hospital
Sustained Virologic Response, Hepatitis B, Chronic
Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients
In the treatment of chronic hepatitis B (CHB), viral suppression is closely related to disease progression, and the lower the viral load, the lower the risk of progression to cirrhosis and hepatocellular carcinoma (HCC).
- Trial name
- REACH (NCT04724785)
- Testing
- only monitoring, monitoring and regimen change if necessary, regimen change
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Chronic Hepatitis B
Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy
This is a multicenter, prospective cohort study to evaluate the efficacy and safety of sequential combination or switch therapy of pegylated interferon alfa-2a in chronic hepatitis B patients with low HBsAg and HBeAg titers after…
- Trial name
- NCT02589652
- Testing
- Pegylated interferon alfa-2a, Pegylated interferon alfa-2a plus Entecavir, Entecavir
- Where
- 17 sites in China
- Volunteers
- 294 people
- Sponsor
- Huashan Hospital
Hepatitis B, Chronic
EFFORT Extension Study
The purpose of this study is to to prove that the long-term efficacy of strategy of treatment adjustment at W24 according to virological response based on ROADMAP concept is better than standard of care strategy.
- Trial name
- EFFORT-Ex (NCT01529255)
- Testing
- telbivudine (ROADMAP), Telbivudine (Standard of Care)
- Where
- 24 sites in China
- Volunteers
- 576 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B, Chronic
A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B
This study is divided into two parts. Phase Ib is a randomized, double-blind, placebo-controlled trial, designed to evaluate the safety, tolerability, pharmacokinetic characteristics, preliminary efficacy, and immunogenicity of…
- Trial name
- NCT06452693
- Testing
- Nucleotide drugs Control group
- Where
- 22 sites in China
- Volunteers
- 162 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis B
Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
Pilot study to assess the antiviral activity and safety of Besifovir dipivoxil 150mg and L-carnitine 660mg compared to Tenofovir Alafenamide 25mg in chronic hepatitis B patients with Nonalcoholic fatty liver
- Trial name
- NCT03604016
- Testing
- Besifovir dipivoxil, L-carnitine, Tenofovir Alafenamide
- Volunteers
- 76 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Hepatitis B, Chronic
Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
The REP 201 protocol is a small exploratory study assessing the antiviral effects and tolerability of REP 2139-Ca when used with a full course of pegylated interferon (48 weeks) in treatment naive patients or in patients already…
- Trial name
- NCT02726789
- Testing
- REP 2139-Ca, pegylated interferon, entecavir
- Volunteers
- 5 people
- Sponsor
- Replicor Inc.
Chronic Hepatitis B
A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects
This is a multicenter, randomized, double-blind, placebo-controlled phase II study, in which all participants are required to use TQA3605 tablets/placebo in combination with entecavir.
- Trial name
- NCT06990776
- Testing
- TQA3605 Tablets, Entecavir dispersible tablets
- Where
- 29 sites in China
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Renal Insufficiency, Tenofovir
TDF Dose Adjustment VS. Switching to TAF in TDF-experienced CHB Patients With Renal Impairment
Tenofovir is a nucleotide analog drug that works against both Human immunodeficiency virus (HIV) and HBV. TDF and TAF are prodrug of Tenofovir.
- Trial name
- NCT04391608
- Testing
- Switching to Tenofovir Alafenamide
- Where
- Thailand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Mahidol University
HBV, Chronic Hepatitis b
A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
This is a multicenter, prospective, real-world study. The study plans to include a total of 2000 patients who meet the inclusion and exclusion criteria, consisting of 1600 treatment-naive patients and 400 treatment-experienced…
- Trial name
- NCT06926647
- Testing
- Nucleos(t)ide Analogues, Interferon alfa, NAs combined with IFNα
- Where
- 85 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Beijing 302 Hospital
Hepatitis B, Chronic
Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Chronic Hepatitis B infection (CHB) is known as the most frequently identified cause of liver disease that predisposes patients to the development of hepatocellular carcinoma (HCC).
- Trial name
- NCT02224456
- Testing
- Tenofovir disoproxil fumarate
- Where
- 19 sites in China
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative
Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B
Background: Chronic infection with the hepatitis B virus may lead to cirrhosis, liver disease, and cancer of the liver. There is no cure for the infection, but several drugs have been approved to treat it.
- Trial name
- NCT01581554
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B, Chronic
ANRS HB07 IP-Cure-B Proof of Concept (PoC) Clinical Trial. Educating the Liver Immune Environment Through TLR8 Stimulation Followed by NUC Discontinuation
The ANRS HB07 IP-cure-B study is a proof of concept Phase II clinical trial in HBeAg negative virally suppressed non-cirrhotic CHB patients.
- Trial name
- IP-CURE-B (NCT05045261)
- Testing
- administration of SLGN in arm C, Discontinuation of NUC treatment in arms B and C
- Where
- 8 sites in France, Germany and 2 more
- Volunteers
- 100 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis B Patients
Dynamic Changes of Serum HBV RNA in Chronic Hepatitis B Patients
Some patients with low-level viremia (LLV) are also likely to develop hepatocellular carcinoma (HCC) or other liver diseases. The relationship between HBV RNA levels and fibrosis in patients with HBV DNA negative or LLV is still…
- Trial name
- NCT05991531
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing Friendship Hospital
Chronic Hepatitis B
Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B
Although the best treatment choice for chronic hepatitis B is not clarified yet, certain therapeutic concepts could be derived from the experience of treating patients with chronic hepatitis C or human immunodeficiency virus…
- Trial name
- NCT00597259
- Testing
- Pegasys plus Entecavir, Entecavir
- Where
- Taiwan
- Volunteers
- 294 people
- Sponsor
- National Taiwan University Hospital
Hepatitis B
Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone
This study is being conducted to compare the safety and effectiveness of the investigational medication LdT (telbivudine) used in combination with adefovir dipivoxil (a drug currently approved by the Food and Drug Administration…
- Trial name
- NCT00376259
- Testing
- telbivudine, adefovir dipivoxil
- Where
- 6 sites in United States, Hong Kong and 3 more
- Volunteers
- 43 people
- Sponsor
- Novartis
Chronic Hepatitis b, Cirrhosis Due to Hepatitis B
The Efficacy and Safety of TAF vs Other NAs in Patients With LVL
Patients with chronic hepatitis B should maximize the inhibition of HBV replication, which could reduce the incidence of liver cancer and liver disease-related complications.
- Trial name
- NCT04501224
- Testing
- Tenofovir alafenamide fumarate, Entecavir or Tenofovir disoproxil fumarate
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Chronic Hepatitis B
Efficacy and Safety of TAF for 48 Weeks in HBeAg Positive CHB Patients
The objective of this clinical study was to observe the changes of HBsAg levels after a sequential 48 weeks-treatment of TAF in ETV experienced CHB patients and to monitor the levels of cytokines such as IFN-λ3, IP-10, IL-12…
- Trial name
- NCT04864366
- Testing
- Tenofovir Alafenamide 25 MG [Vemlidy]
- Where
- 3 sites in China
- Volunteers
- 150 people
- Sponsor
- Huashan Hospital
Chronic Hepatitis b
Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)
This study is a single-center, randomized, prospective, open-label Phase 2 Clinical trial to evaluate efficacy and safety of ETV and TQ-A3334 combinated with/without inhibitor of TQ-B2450 versus ETV alone in chronic hepatitis B…
- Trial name
- Neptune (NCT04202653)
- Testing
- ETV, TQ-A3334, TQ-B2450
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Tongji Hospital
Chronic Hepatitis B
Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg≤20IU/ml or HBsAg Negative Without Serological Conversion
The objective of this study is to assess the immunogenicity and safety of TVAX-008 injection in antiviral untreated/untreated chronic hepatitis B patients with HBsAg≤20 IU/mL, or HBsAg negative and no seroconversion through an…
- Trial name
- NCT07204236
- Testing
- TVAX-008
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Grand Theravac Life Sciences (Nanjing) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.